Page 286 - Read Online

CONCLUSION through a mechanism involving excessive activation of extrasynaptic
NR2B‑containing NMDA receptors. J Neurosci 2011;31:6627‑38.
10. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R,
AChE inhibitors ameliorate the cognitive and Hansen LA, Katzman R. Physical basis of cognitive alterations in
psychiatric symptoms in AD patients through increased Alzheimer’s disease: synapse loss is the major correlate of cognitive
synaptic ACh levels to activate AChRs and protect impairment. Ann Neurol 1991;30:572‑80.
against glutamate neurotoxicity and inflammation, 11. Contestabile A. The history of the cholinergic hypothesis. Behav
Brain Res 2011;221:334‑40.
whereas memantine appears to mainly protect against 12. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease:
excitotoxicity and consequent neurodegeneration. progress and problems on the road to therapeutics. Science
AChE inhibitors exert neuroprotective effects by 2002;297:353‑6.
improving cholinergic mediated memory function, 13. Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers
enhancing glutamatergic responses and acting as cause localized Ca(2+) elevation, missorting of endogenous Tau
into dendrites, Tau phosphorylation, and destruction of microtubules
anti‑inflammatory agent. Memantine is efficient at and spines. J Neurosci 2010;30:11938‑50.
preventing the deleterious actions of Aβ oligomers 14. Drever BD, Riedel G, Platt B. The cholinergic system and
mainly due to its selectivity for the extrasynaptic hippocampal plasticity. Behav Brain Res 2011;221:505‑14.
NMDARs. Therefore, AChE inhibitors could be used for 15. Micheau J, Marighetto A. Acetylcholine and memory: a long,
complex and chaotic but still living relationship. Behav Brain Res
the earlier to later stages of AD, but memantine should 2011;221:424‑9.
preferentially be used only in the later phase of AD. 16. Schliebs R, Arendt T. The cholinergic system in aging and neuronal
degeneration. Behav Brain Res 2011;221:555‑63.
Acknowledgments 17. Hasselmo ME, Sarter M. Modes and models of forebrain cholinergic
neuromodulation of cognition. Neuropsychopharmacology
This work was supported by research grants from the State 2011;36:52‑73.
Key Development Program for Basic Research of China 18. Easton A, Douchamps V, Eacott M, Lever C. A specific role for
(2011CB510000), the National Natural Science Foundation septohippocampal acetylcholine in memory? Neuropsychologia
2012;50:3156‑68.
of China (81271428, 81471292, and 81430021), and a 19. Li S, Cullen WK, Anwyl R, Rowan MJ. Muscarinic acetylcholine
grant supported by assisting research project of science receptor‑dependent induction of persistent synaptic enhancement
and technology for Xinjiang (201591160). in rat hippocampus in vivo. Neuroscience 2007;144:754‑61.
20. Hayes J, Li S, Anwyl R, Rowan MJ. A role for protein kinase A and
Financial support and sponsorship protein kinase M zeta in muscarinic acetylcholine receptor‑initiated
Nil. persistent synaptic enhancement in rat hippocampus in vivo.
Neuroscience 2008;151:604‑12.
21. Nakauchi S, Sumikawa K. Endogenously released ACh and
Conflicts of interest exogenous nicotine differentially facilitate long‑term potentiation
There are no conflicts of interest. induction in the hippocampal CA1 region of mice. Eur J Neurosci
2012;35:1381‑95.
REFERENCES 22. Kanju PM, Parameshwaran K, Sims‑Robinson C, Uthayathas S,
Josephson EM, Rajakumar N, Dhanasekaran M, Suppiramaniam V.
Selective cholinergic depletion in medial septum leads to impaired
1. Alzheimer’s A. 2013 Alzheimer’s disease facts and figures. Alzheimers long term potentiation and glutamatergic synaptic currents in the
Dement 2013;9:208‑45. hippocampus. PLoS One 2012;7:e31073.
2. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s 23. Fernandez de Sevilla D, Nunez A, Borde M, Malinow R, Buno W.
disease. Cochrane Database Syst Rev 2006;25:CD001190. Cholinergic‑mediated IP3‑receptor activation induces long‑lasting
3. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med synaptic enhancement in CA1 pyramidal neurons. J Neurosci
2010;362:329‑44. 2008;28:1469‑78.
4. Perl DP. Neuropathology of Alzheimer’s disease. Mt Sinai J Med 24. Buchanan KA, Petrovic MM, Chamberlain SE, Marrion NV,
2010;77:32‑42. Mellor JR. Facilitation of long‑term potentiation by muscarinic
5. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, M(1) receptors is mediated by inhibition of SK channels. Neuron
Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide 2010;68:948‑63.
concentration as a predictor of synaptic change in Alzheimer’s 25. Fernandez de Sevilla D, Buno W. The muscarinic long‑term
disease. Am J Pathol 1999;155:853‑62. enhancement of NMDA and AMPA receptor‑mediated transmission
6. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, at Schaffer collateral synapses develop through different intracellular
Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid mechanisms. J Neurosci 2010;30:11032‑42.
as a determinant of severity of neurodegeneration in Alzheimer’s 26. Yamazaki Y, Jia Y, Niu R, Sumikawa K. Nicotine exposure in vivo
disease. Ann Neurol 1999;46:860‑6. induces long‑lasting enhancement of NMDA receptor‑mediated
7. Shankar GM, Li S, Mehta TH, Garcia‑Munoz A, Shepardson NE, currents in the hippocampus. Eur J Neurosci 2006;23:1819‑28.
Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, 27. Aramakis VB, Metherate R. Nicotine selectively enhances
Walsh DM, Sabatini BL, Selkoe DJ. Amyloid‑beta protein dimers NMDA receptor‑mediated synaptic transmission during postnatal
isolated directly from Alzheimer’s brains impair synaptic plasticity development in sensory neocortex. J Neurosci 1998;18:8485‑95.
and memory. Nat Med 2008;14:837‑42. 28. Shen JX, Yakel JL. Nicotinic acetylcholine receptor‑mediated
8. Klyubin I, Ondrejcak T, Hayes J, Cullen WK, Mably AJ, Walsh DM, calcium signaling in the nervous system. Acta Pharmacol Sin
Rowan MJ. Neurotransmitter receptor and time dependence of the 2009;30:673‑80.
synaptic plasticity disrupting actions of Alzheimer’s disease Abeta 29. Andre JM, Leach PT, Gould TJ. Nicotine ameliorates NMDA receptor
in vivo. Philos Trans R Soc Lond B Biol Sci 2014;369:20130147. antagonist‑induced deficits in contextual fear conditioning through
9. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, high‑affinity nicotinic acetylcholine receptors in the hippocampus.
Selkoe DJ. Soluble Abeta oligomers inhibit long‑term potentiation Neuropharmacology 2011;60:617‑25.

278 Neuroimmunol Neuroinflammation | Volume 2 | Issue 4 | October 15, 2015 Neuroimmunol Neuroinflammation | Volume 2 | Issue 4 | October 15, 2015 279